This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

InOncology.com

ESMO 2017

EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS

This event has ended

The European Society for Medical Oncology (ESMO) 2017 Congress took place on 8–12 September 2017 at Conference Center IFEMA, Madrid, Spain.

Boehringer Ingelheim presented an expert roundtable symposium in thoracic cancers which was chaired by Prof. Silvia Novello and included presentations with panel discussion from Prof. Nicolas Girard, Prof. Shirish Gadgeel and Prof. Sanjay Popat. A post-meeting delayed webcast of the symposium including panel discussions is featured below.

 

ESMO Symposium Webcast

What factors should be considered in choosing the sequence of EGFR TKIs for EGFR M+ NSCLC patients?

What factors should be considered in choosing the sequence of EGFR TKIs for EGFR M+ NSCLC patients?

5 min
Rate this

Panel discussion: EGFR TKIs for patients with advanced NSCLC and the importance of overall survival data

2 min 20 sec
Rate this

EGFR, epidermal growth factor receptor; EGFR M+, epidermal growth factor receptor mutation positive; NSCLC, non small cell lung carcinoma; TKI, tyrosine kinase inhibitor

What is the rationale for use of EGFR TKIs in squamous NSCLC?

What is the rationale for use of EGFR TKIs in squamous NSCLC?

1 min 9 sec
Rate this

Panel discussion: current therapeutic algorithm for squamous NSCLC treatment and considerations for treatment choice

3 min 44 sec
Rate this

EGFR, epidermal growth factor receptor; NSCLC, non small cell lung carcinoma; TKI, tyrosine kinase inhibitor

What do you think of the anti-angiogenic approach in treating MPM?

What do you think of the anti-angiogenic approach in treating MPM?

2 min 29 sec
Rate this

Panel discussion: appropriate angiogenic markers, the role of immunotherapy and the potential of oral drugs in MPM

6 min 16 sec
Rate this

MPM, malignant pleural mesothelioma

Download the symposium slide set below:

Symposium agenda

Expert roundtable in thoracic cancers: finding our paradigms in an evolving landscape

  1. Introduction and welcome Prof Silvia Novello (Chair)
  2. Tackling urgent questions in the treatment of adenocarcinoma and squamous cell carcinoma Prof Nicolas Girard and Prof Shiresh Gadgeel
  3. Treating unresectable malignant pleural mesothelioma: current options and future outlook Dr Sanjay Popat 
  4. Summary and meeting close Prof Silvia Novello (Chair)

Sequencing Infographic

View this video to see how the landscape for treatment for EGFRM+ NSCLC has evolved, and how insights from afatinib clinical trials can inform treatment sequencing for patients with EGFRM+ NSCLC. The video includes recent data presented at ESMO by Sequist et al.

Rate this

For more information on afatinib clinical trial data, please click here.

Presentations

  • Saturday 9 September 2017

    Poster discussion session

    • Paediatric neuroectodermal and mesenchymal tumours

      Biomarker prevalence study and Phase I trial of afatinib** in children with malignant tumours

      Nysom et al.

  • Monday 11 September 2017

    Poster discussion session

    • Mesothelioma

      Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib* (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)

      Novello et al.

  • Saturday 9 September 2017

    Poster display session

    • NSCLC

      Activity of afatinib in heavily pretreated patients (pts) with HER2 mutation-positive (HER2m+) advanced non-small cell lung cancer (NSCLC): findings from a global named patient use (NPU) program

      Peters et al.

       

      Subsequent therapies post-afatinib among patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC in LUX-Lung (LL) 3, 6 and 7

      Sequist et al.

       

      Investigation of biomarkers in patients with adenocarcinoma of the lung receiving nintedanib according to approved label: non-interventional LUME-BioNIS study

      Reck et al.

  • Sunday 10 September 2017

    Poster display session

    • HNSCC

      Long-term response to second-line afatinib in patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): analysis of the LUX-Head & Neck 1 (LHN1) trial

      Machiels et al.

    • Urothelial carcinoma

      Afatinib in patients with advanced or metastatic urothelial carcinoma (UC) with genetic alterations in ERBB receptors 1–3 who failed on platinum-based chemotherapy: The Phase II LUX-Bladder 1 trial

      Font et al.

  • Monday 11 September 2017

    Poster display session

    • NSCLC; breast cancer; solid tumours

      A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumours, hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer (BC; +/-endocrine therapy), or non-small-cell lung cancer (NSCLC)

      Prat et al.

Didn’t make ESMO 2017? Find out more about upcoming oncology events.

Click here to find out more about other oncology meetings, congresses, symposia and activities sponsored by Boehringer Ingelheim.

*Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

 

**Afatinib is approved in more than 70 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

Afatinib is being investigated in urothelial carcinoma (UC) and head and neck squamous cell carcinoma (HNSCC) and is not approved for these uses. The efficacy and safety of afatinib in UC and HNSCC have not been established.